Recommendations of care for patients with prediabetes

Czech version

Authors: T. Pelikánová
Published in: Vnitř Lék 2012; 58(3): 237-240
Category: Guidelines

Sources

1. Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009; 9: 193–199.

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35: S11–S63.

3. Borai A, Livingstone C, Abdelaal F et al. The relationship between glycosylated haemoglobin (HbA_1c) and measures of insulin resistance across a range of glucose tolerance. Scand J Clin Lab Invest 2011; 71: 168–172.

4. Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Circulation 2007; 116: 151–157.

5. Brambilla P, La Valle E, Falbo R et al. Normal Fasting Plasma Glucose and Risk of Type 2 diabetes. Diabetes Care 2011; 34: 1372–1374.

6. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am 2011; 95: 289–297.

7. Colagiuri S. Epidemiology of prediabetes. Med Clin North Am 2011; 95: 299–307.

8. Faerch K, Vaag A, Holst JJ et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008; 51: 853–861.

9. Faerch K, Vaag A, Holst JJ et al. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 2009; 32: 439–444.

10. Garber AJ. Hypertension and lipid management in prediabetic states. J Clin Hypertens 2001; 13: 270–224.

11. Heianza Y, Hara S, Arase Y et al. HbA1c 5.7–6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011; 378: 147–155.

12. James C, Bullard KM, Rolka DB et al. Implications of Alternative Definitions of Prediabetes for Prevalence in U.S. Adults. Diabetes Care 2011; 34: 387–391.

13. Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55: 363–369.

14. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431–1437.

15. Priya M, Mohan Anjana R, Pradeepa R et al. Comparison of capillary whole blood versus venous plasma glucose estimations in screening for diabetes mellitus in epidemiological studies in developing countries. Diabetes Technol Ther 2011; 13: 586–591.

16. Ratner RE, Sathasivam A. Treatment recommendations for prediabetes. Med Clin North Am 2011; 95: 385–395.

17. Tankova T, Chakarova N, Atanassova I et al. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract 2011; 92: 46–52.

18. Widén EI, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354–358.